On the other hand, the use of systemic anti-HER2 treatment is questionable, since DCIS is only a non-obligate precursor of invasive breast cancer, resulting in potential overtreatment for the majority of HER2-positive DCIS patients. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.